These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22283755)

  • 1. Disturbed function of GABAergic interneurons in schizophrenia: relevance for medical treatment?
    Genius J; Giegling I; Benninghoff J; Rujescu D
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1549-56. PubMed ID: 22283755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic drugs for schizophrenia treatment.
    Gibert-Rahola J; Villena-Rodriguez A
    Actas Esp Psiquiatr; 2014; 42(5):234-41. PubMed ID: 25179095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapies for schizophrenia: understanding the glutamatergic synapse and potential targets for altering N-methyl-D-aspartate neurotransmission.
    Hui C; Wardwell B; Tsai GE
    Recent Pat CNS Drug Discov; 2009 Nov; 4(3):220-38. PubMed ID: 19891601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From glutamatergic dysfunction to cognitive impairment: boundaries in the therapeutic of the schizophrenia.
    Gaspar PA; Bustamante ML; Rojo LE; Martinez A
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1543-8. PubMed ID: 22283759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: II. Glutamate (Ant)agonists.
    Carfagno ML; Hoskins LA; Pinto ME; Yeh JC; Raffa RB
    Ann Pharmacother; 2000 Jun; 34(6):788-97. PubMed ID: 10860140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamatergic agents for schizophrenia: current evidence and perspectives.
    Zink M; Correll CU
    Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neuropathology of schizophrenia.
    Bachus SE; Kleinman JE
    J Clin Psychiatry; 1996; 57 Suppl 11():72-83. PubMed ID: 8941174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
    Goff DC; Coyle JT
    Am J Psychiatry; 2001 Sep; 158(9):1367-77. PubMed ID: 11532718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-Target Approach for Drug Discovery against Schizophrenia.
    Kondej M; Stępnicki P; Kaczor AA
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30309037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schizophrenia: Basic and Clinical.
    Coyle JT
    Adv Neurobiol; 2017; 15():255-280. PubMed ID: 28674984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of NMDA receptors in new treatments for schizophrenia.
    Hashimoto K
    Expert Opin Ther Targets; 2014 Sep; 18(9):1049-63. PubMed ID: 24965576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
    Chaki S; Hikichi H
    Curr Pharm Des; 2011; 17(2):94-102. PubMed ID: 21355835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular pathology of schizophrenia].
    Uezato A; Nishikawa T
    Nihon Rinsho; 2013 Apr; 71(4):591-8. PubMed ID: 23678584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
    Kolomeets NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
    Hashimoto K; Iyo M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.